Drug Type Small molecule drug |
Synonyms ML294 |
Target |
Action inhibitors |
Mechanism DAGL-β inhibitors(diacylglycerol lipase beta inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC28H28N4O2 |
InChIKeyMXVVJNJNDCJCFS-UHFFFAOYSA-N |
CAS Registry1402612-56-9 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Decrease in appetite | Preclinical | United States | 25 Feb 2013 | |
| Memory Disorders | Preclinical | United States | 25 Feb 2013 | |
| Pain | Preclinical | United States | 25 Feb 2013 | |
| psychological symptoms behavior compulsive behavior addiction | Preclinical | United States | 25 Feb 2013 | |
| Sensation Disorders | Preclinical | United States | 25 Feb 2013 |





